NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. draws upon decades of collective, scientific, and drug-development experience to address very high unmet needs of patients and bring improved health to patients. The U.S. Food and Drug Administration (“FDA”) has additionally granted Breakthrough Therapy designation, a Special Protocol Agreement, and a Biomarker Letter of Support for NRX-101, an investigational medicine for the treatment of severe bipolar depression in patients with acute suicidal ideation and behavior (ASIB) after initial stabilization with ketamine or other effective therapy. NRx Pharmaceuticals is led by executives who have held leadership roles at Lilly, Pfizer, and Novartis as well as major investment banking institutions.

网站

https://www.nrxpharma.com

NRx Pharmaceuticals, Inc.的外部链接

所属行业

生物技术研究

规模

11-50 人

总部

Wilmington，Delaware

类型

私人持股

创立

2015

领域

Pharmaceutical Development、CNS、Medical Device Development、Acute Suicidality、COVID-19、ARDS和PTSD